Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.
Jan 8, 2015
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium